0001062993-22-007530.txt : 20220311 0001062993-22-007530.hdr.sgml : 20220311 20220311184223 ACCESSION NUMBER: 0001062993-22-007530 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220309 FILED AS OF DATE: 20220311 DATE AS OF CHANGE: 20220311 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Montecalvo Antonio S. CENTRAL INDEX KEY: 0001759261 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37906 FILM NUMBER: 22734660 MAIL ADDRESS: STREET 1: C/O ORGANOGENESIS INC. STREET 2: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Organogenesis Holdings Inc. CENTRAL INDEX KEY: 0001661181 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 BUSINESS PHONE: 781-575-0775 MAIL ADDRESS: STREET 1: 85 DAN ROAD CITY: CANTON STATE: MA ZIP: 02021 FORMER COMPANY: FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp. DATE OF NAME CHANGE: 20151215 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2022-03-09 0001661181 Organogenesis Holdings Inc. ORGO 0001759261 Montecalvo Antonio S. C/O ORGANOGENESIS HOLDINGS INC. 85 DAN ROAD CANTON MA 02021 0 1 0 0 Vice President, Health Policy Class A Common Stock 2022-03-09 4 S 0 10000 8.52 D 73221 D Class A Common Stock 2022-03-10 4 M 0 46103 3.46 A 119324 D Class A Common Stock 2022-03-10 4 M 0 22401 3.46 A 141725 D Class A Common Stock 2022-03-10 4 S 0 97436 8.39 D 44289 D Stock Option (Right to Buy) 3.46 2022-03-10 4 M 0 46103 0 D 2027-05-04 Class A Common Stock 46103 55397 D Stock Option (Right to Buy) 3.46 2022-03-10 4 M 0 22401 0 D 2027-05-04 Class A Common Stock 22401 78175 D The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.54, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.34 to $8.42, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018. The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017. /s/ William R. Kolb, Attorney-in-Fact 2022-03-11